Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US
A prospective, randomised, controlled, single-blind, multi-site clinical study employing Neuromuscular Electrical Stimulation (NMES) to stimulate the pelvic floor muscles of women suffering from stress urinary incontinence. Approximately one-hundred and eighty (180) female patients diagnosed with stress urinary incontinence will be enrolled in this study. All patients who are considered eligible to participate in the clinical study and give consent will be randomised to complete either a 12-week treatment programme with the Neurotech Vital Compact device or a 12-week treatment programme with the itouch Sure Pelvic Floor Exerciser. The 12-week treatment programme will be completed by the subjects at home with treatment with the device in accordance with the device Instructions for Use.
Study Start Date
Estimated Completion Date
- Device: itouch Sure Pelvic Floor Exerciser
- Device: Neurotech Vital Compact
- Urology: Voiding Dys/Incontinence
- Physician Assistant: Urology
- Urinary Incontinence
Bio-Medical Research, Ltd. -- BMR-13-1001
Bio-Medical Research, Ltd.
1. Subjects who are female and at least 18 years of age, and not more than 65 years of
2. Subjects who have signed the informed consent form prior to any study related
3. Subjects who have previously tried and failed to improve their condition using Kegel
4. Subjects who have been clinically diagnosed with stress urinary incontinence and
demonstrate a greater than or equal to 3g urine leakage and a less than or equal to
90g urine leakage (>3g and < 90g) following a bladder-filling protocol and then a
standardised stress test (provocative pad weight test) at the baseline assessment.
5. Subjects who score 9 or less (<9) out of 18 for the Urge Incontinence Questions and
are confirmed as having predominant stress urinary incontinence on the Medical,
Epidemiologic and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire
completed at the screening assessment.
6. Subjects with a Body Mass Index of ? 35 kg/m2.
7. Subjects of child-bearing potential who are using a highly effective contraceptive
method (established use of oral, injected, implanted hormonal method of contraception
or barrier method of contraception with spermicide).
8. Subjects who are willing not to seek any other treatment for stress incontinence
during the study period.
9. Subjects who are able to give voluntary, written informed consent to participate in
this study and from whom consent has been obtained.
10. Subjects who are able to understand this study and are willing to complete all the
1. Subjects who have an existing medical condition that would compromise their
participation in the study, e.g. reduced sensory perception in the contact area of
the stimulation electrodes scars or vaginal tissue wounds, lesions or
inflamed/infected areas in the contact area of the stimulation electrodes vaginal
bleeding between menstrual periods uncontrolled diabetes.
2. Subjects who have a physical condition that would make them unable to perform the
study procedures, e.g. pelvic or hip surgery within the past 6 weeks.
3. Subjects who have been diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
4. Subjects with a history of an underlying neurological condition, e.g. Multiple
Sclerosis, Parkinson's disease, epilepsy.
5. Subjects with any bladder abnormality that would affect the urinary flow through the
lower urinary tract including signs or symptoms of an active urinary tract infection,
abnormal bladder capacity (e.g., >300 cc), post void residual volume >200 cc, spastic
bladder, vesico-ureteral reflux or bladder stones.
6. Subjects with a blood clotting disorder or who are taking anti-coagulant medications.
7. Subjects who have previously had any uro-gynaecological related surgery that would
affect the pelvic floor muscles or urinary flow through the urethra (excluding
8. Subjects who have previously had pelvic floor radiation.
9. Subjects who have previously been treated for stress incontinence with injectable
bulking agents and/or vaginal probes within the past 6 months.
10. Subjects with a clinical diagnosis of prolapse greater than Stage 2.
11. Subjects who are pregnant or could be pregnant.
12. Subjects who are less than 6 months post-partum or who are lactating.
13. Subjects who have any conductive intra-uterine devices or metal implants in the
pelvic area, including hip and lumbar spine.
14. Subjects with pelvic pain or fibromyalgia or paravaginal defect.
15. Subjects with an active implanted medical device (i.e. pacemaker, insulin pump etc.)
or conditions that may be adversely affected by electrical stimulation (e.g. cardiac
16. Subjects with a current or active history of pelvic cancer and/or subjects with a
life expectancy of less than 12 months.
17. Subjects who are currently involved in any injury litigation claims.
18. Subjects who have participated in a clinical study in the last 3 months or any
previous clinical study with Bio-Medical Research Ltd.
19. Subjects who have been committed to an institution by virtue of an order issued
either by the courts or by an authority.
18 Years to 65 Years
Accepts Healthy Volunteers
Study Locations and Contact Information (12)
|AccuMed Research Associates - Garden City, New York||41.5 miles||Leanne Cossu CRCemail@example.com|
|Hartford Hospital - Hartford, Connecticut||48.4 miles||Alison Champagne||Nonefirstname.lastname@example.org|
|Temple University - Philadelphia, Pennsylvania||129.9 miles||Sarmina Hassan PhDemail@example.com|
|Boston Clinical Trials - Boston, Massachusetts||132.3 miles||Irene Axelrod||Nonefirstname.lastname@example.org|
|Lyndhurst Gynecological Associates - Winston-Salem, North Carolina||523.2 miles||Kathy Pooleemail@example.com|
|Medical University of South Carolina - Charleston, South Carolina||691.2 miles||Betty Oswaldfirstname.lastname@example.org|
|Renaissance Health Surgical Associates - South Pittsburg, Tennessee||802.6 miles||Kristin Williams CRNPemail@example.com|
|The Jackson Clinic - Jackson, Tennessee||926.0 miles||Wendy Pinsonfirstname.lastname@example.org|
|University of South Florida Medical Center - Tampa, Florida||1,058.1 miles||Caroline A Youngemail@example.com|
|Altus Research - Lake Worth, Florida||1,084.5 miles||Gina Piercefirstname.lastname@example.org|
|Maricopa Integrated Health Systems - Phoenix, Arizona||2,181.0 miles||Maureen Suttonemail@example.com|
|University of California Irvine Medical Center - Orange, California||2,477.9 miles||Pamela Rumneyfirstname.lastname@example.org|